Vicky Xia and Joel Ranck of BioPlan share some first insights from the CPHI Annual Report

Having already benefitted from a COVID-based boom in the last two years, outsourcing of biologics globally is set to continue growing significantly in 2023. No production cliff is expected, even as COVID-related contracts reduce in scale, but the rapid growth of China’s biologics sector will slow.